British Bio Seeking Partners For Three Projects After Zacutex Termination
Executive Summary
British Biotech will focus its discovery research on metallo-enzyme inhibition programs and seek partnerships for several compounds following the discontinuation of the pancreatitis therapy Zacutex (lexipafant), the firm announced March 25.
You may also be interested in...
Schering Gains British Biotech's Marimastat, Drops U.S. Fareston Marketing
Schering-Plough will assume all European and U.S. regulatory filings for British Biotech's cancer therapy marimastat under a collaboration announced September 7 to develop and market British Biotech's matrix metalloproteinase inhibitors.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011